Physician profile
Shantanu Sinha
NPI 1124029426
$10,915.24
in general payments reported to CMS, 2019-2025
40 companies · $862 in 2025
The $862 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,924 · 2020: $947 · 2021: $779 · 2022: $500 · 2023: $875 · 2024: $1,028 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735 · Education: $29.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.43 |
| Education | $29.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $5,253.33 | 2019-2020 | |
| Medtronic, INC. | $1,062.49 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Linq II |
| Medtronic Vascular, INC. | $708.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $517.63 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $438.49 | 2019-2025 | |
| Pfizer INC. | $338.46 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $285.84 | 2019-2023 | |
| Boston Scientific Corporation | $268.68 | 2020-2024 | Watchman Access System, Watchman Flx, Varithena Administration Pack |
| Amgen INC. | $266.38 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $195.75 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.68 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $138.93 | 2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.24 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $127.52 | 2023-2025 | Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $84.26 | 2019-2025 | Evkeeza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.47 | 2020-2024 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $66.74 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $66.66 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $65.46 | 2019-2025 | Farxiga |
| Lundbeck LLC | $62.16 | 2019 | |
| Merck Sharp & Dohme LLC | $53.59 | 2024-2025 | Winrevair |
| Kowa Pharmaceuticals America, INC. | $53.52 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.55 | 2023-2024 | Jynarque |
| Atricure, INC. | $44.02 | 2022 | |
| Astellas Pharma US INC | $43.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.65 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $40.46 | 2022-2023 | Onpattro |
| Venclose INC. | $36.79 | 2020 | |
| Tactile Systems Technology INC | $30.73 | 2021-2023 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $30.29 | 2020-2024 | Nexletol |
| Bardy Diagnostics, INC. | $30.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $29.45 | 2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $21.89 | 2022 | |
| Calliditas Therapeutics US INC. | $21.63 | 2025 | Tarpeyo |
| Philips North America LLC | $20.83 | 2019 | |
| Ardelyx, INC. | $18.65 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Baxter Healthcare | $14.72 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Abbvie INC. | $11.23 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $9.84 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shantanu Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.